Parents in the United States who want to vaccinate their young children against Covid-19 this fall may face a growing set of ...

Having multiple chronic conditions may signal higher odds of disease flare and lower odds of achieving remission in patients ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

The potential move to rescind authorization of Pfizer's vaccine could leave some kids in the U.S. with no available shots ...

Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Key PointsPfizer's free cash flow should improve.The drugmaker's lower leverage ratio target gives it greater financial flexibility.New products should cushion the blow from Pfizer's looming patent ...

Pfizer’s second quarter results were well received by the market, as the company outperformed Wall Street’s expectations for ...

Pfizer stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

U.S. Health Secretary Robert F. Kennedy Jr., a longtime vaccine critic, canceled $500 million in government-funded research ...